REVIEW OF DECISIONS

BOARD MEETING
26-27 June 2019, Geneva
Decision 1: Consent Agenda: Delegation of Board Chair Recruitment to Governance Committee

In line with the process for the appointment of the Board Chair endorsed by the Board in June 2017, as read with Section 4.B of the Governance Committee Charter, the Gavi Alliance Board:

a) **Delegated** to the Governance Committee the authority to set up and oversee the process for the recruitment of a Board Chair to succeed Dr Ngozi Okonjo-Iweala at the end of her term on 31 December 2020; and

b) **Delegated** to the Governance Committee the authority to establish a Search Committee for this purpose.
Decision 2: Consent Agenda: Committee Chair Appointments

The Gavi Alliance Board:

a) **Reappointed** Nina Schwalbe as a member of the Evaluation Advisory Committee effective 1 January 2020 through 30 June 2021.

b) **Appointed** Nina Schwalbe as Chair of the Evaluation Advisory Committee effective 1 July 2019 through 30 June 2021.
Decision 3: Consent Agenda: Board/Committee member nominations (1/7)

The Gavi Alliance Board:

a) **Appointed** the following Board Members:

- **Ferozuddin Feroz** of Afghanistan as Board member representing the developing country constituency in the seat currently held by Suad Youusif Abdallah Alkarib of Sudan, effective immediately and until 31 December 2020.

- **Arsen Torosyan** of Armenia as Board member representing the developing country constituency in the seat currently held by Sergey Khachatryan of Armenia, effective immediately and until 31 December 2021.

- **Peter Salama** as Board Member representing WHO in the seat currently held by Souyma Swaminathan, effective immediately and until his successor is appointed.
Decision 3: Consent Agenda: Board/Committee member nominations (2/7)

- **Craig Burgess** as Board Member representing the civil society organisations constituency in the seat currently held by Clarisse Loe Loumou, effective 1 July 2019 and until 30 June 2021.

- **Irene Koek** as Board Member representing the United States on the donor constituency anchored by the United States in the seat currently held by Sarah Goulding of Australia, effective 1 July 2019 and until 30 June 2021.

- **Muhammad Pate** as Board Member representing the World Bank in the seat currently held by Tim Evans, effective 1 July 2019 and until his successor is appointed.
Decision 3: Consent Agenda: Board/Committee member nominations (3/7)

b) **Amended the appointment** of the following Board member:

- **Afsaneh Beschloss** as an Unaffiliated Board Member in the seat formerly held by Yifei Li, effective 1 January 2020 and until 31 December 2022.
Decision 3: Consent Agenda: Board/Committee member nominations (4/7)

c) **Appointed** the following Alternate Board Members:

- **Asaad Hafeez** of Pakistan as Alternate Board member representing the developing country constituency in the seat currently held by Aamer Mehmood Kiani of Pakistan, effective immediately and until 31 December 2020.

- **Maty Dia** as Alternate Board Member representing the civil society organisations constituency in the seat currently held by Craig Burgess, effective 1 July 2019 and until 30 June 2021.

- **Sarah Goulding** as Alternate Board Member representing Australia on the donor constituency anchored by the United States in the seat currently held by Irene Koek of the United States, effective 1 July 2019 and until 30 June 2021.

- **Etleva Kadili** as Alternate Board Member representing UNICEF in the seat currently held by Ted Chaiban, effective 1 October 2019 and until her successor is appointed.
Decision 3: Consent Agenda: Board/Committee member nominations (5/7)

d) **Appointed** the following to the Market-Sensitive Decisions Committee effective immediately:

- **Amir Aman Hagos** (Board Member) until 31 December 2019.
- **Asaad Hafeez** (Alternate Board Member) until 31 December 2019.

e) **Appointed** the following to the Market-Sensitive Decisions Committee effective 1 July 2019:

- **Craig Burgess** (Board Member) until 31 December 2019.

f) **Appointed** the following to the Market-Sensitive Decisions Committee effective 1 October 2019:

- **Etleva Kadilli** (Alternate Board Member) until 31 December 2019.
g) **Reappointed** the following to the Market-Sensitive Decisions Committee effective 1 July 2019:

- **Irene Koek** (Board Member) until 31 December 2019.

h) **Appointed** the following to the Governance Committee effective 1 July 2019:

- **Craig Burgess** (Board Member) until 31 December 2019.
- **Susan Silbermann** (Board Member) until 31 December 2019.

i) **Appointed** the following to the Audit and Finance Committee effective 1 July 2019:

- **Maty Dia** (Alternate Board Member) until 31 December 2019.
Decision 3: Consent Agenda: Board/Committee member nominations (7/7)

j) **Reappointed** the following to the Audit and Finance Committee effective 1 July 2019:
   - Irene Koek (Board Member) until 31 December 2019.

k) **Appointed** the following to the Evaluation Advisory Committee effective 1 July 2019:
   - Maty Dia (Alternate Board Member) until 31 December 2019.
   - Marta Nunes (Board Member) until 31 December 2019.
Decision 4: Consent Agenda: Appointment of Treasurer

The Gavi Alliance Board:

**Appointed** Assietou Diouf as Treasurer with individual signatory authority, effective immediately and until her successor is appointed and qualified.
Decision 5: Consent Agenda: Evaluation Advisory Committee Terms of Reference

The Gavi Alliance Board:

**Approved** the updated and revised Evaluation Advisory Committee Terms of Reference as set out in Annex A to Doc 01d, effective from 1 July 2019.
Decision 6: Consent Agenda: Appeals Tribunal

The Gavi Alliance Board:

a) **Approved** the Gavi Alliance Appeals Tribunal Statute and Rules of Procedure set out at Annex B to Doc 01d;

b) **Reappointed** Claude Rouiller as a member of the Gavi Appeals Tribunal effective immediately for a term of five years;

c) **Reappointed** Anne Trebilcock as a member of the Gavi Appeals Tribunal effective immediately for a term of three years;

d) **Appointed** Chris de Cooker as a member of the Gavi Appeals Tribunal effective immediately for a term of five years;

e) **Appointed** Jenny Schokkenbroek as a member of the Gavi Appeals Tribunal effective immediately for a term of five years; and

f) **Appointed** Michael Wolf as a member of the Gavi Appeals Tribunal effective immediately for a term of five years.
Decision 7: Consent Agenda: Audit & Investigations
Terms of Reference

The Gavi Alliance Board:

Approved the revised Audit and Investigations Terms of Reference as set out in Annex C to Doc 01d.
Decision 8: Consent Agenda: Currency Hedging Policy

The Gavi Alliance Board:

Approved amendments to the Currency Hedging Policy as set out in Annex D to Doc 02d.
Decision 9: Consent Agenda: Gavi Evaluation Policy

The Gavi Alliance Board:

**Approved** the revised and updated Gavi Evaluation Policy as set out in Annex E to Doc 01d, effective from 1 July 2019.
Decision 10: Consent Agenda: Cold Chain Equipment Optimisation Platform

The Gavi Alliance Board:

Approved the use of unallocated or underspent funds under the Cold Chain Equipment Optimisation Platform to support a learning agenda to evaluate innovative cold chain equipment technologies and approaches that the Alliance may choose to scale in the next strategic period.
Decision 11: Consent Agenda: Financial Update (1/2)

The Gavi Alliance Board:

a) **Approved**, within the overall Partners Engagement Framework:
   i. A budget of US$ 19.0 million for UNICEF Supply Division fees for the procurement of vaccines and related devices in 2020, and
   ii. A budget of US$ 4.3 million for UNICEF Supply Division fees for the procurement of cold chain equipment for 2020.
   iii. That the budgetary amounts approved by the Board in the Board Meeting of 29-30 November 2017, for each component of the Gavi Engagement Framework and Budget for Partners and Secretariat for 2018 and separately for 2019, be now treated as an overall Budget amount which may be utilised over both years.
   iv. That capital expenditure of the Secretariat in excess of the capital expenditure budget can be incurred within the overall amount of the Secretariat Engagement Framework and Capital Expenditure budgets for both years.
b) Noted that the Audit and Finance Committee reviewed the financial implications of the recommendations as set out in Figure 1 in Doc 2a (AFC, 25 April 2019) and concluded that these could be approved by the Board in accordance with the Programme Funding Policy, if so recommended by the Programme and Policy Committee.
Decision 12: Gavi 5.0: The Alliance’s 2021-2025 Strategy

The Gavi Alliance Board:

Approved the framework for the Alliance strategy 2021-2025 (‘strategy one-pager’) as set out in Doc 06, as amended by discussions at the Board.
Decision 13: Gavi 5.0: The Alliance’s 2021-2025 Strategy (1/2)

As part of the discussion on the high-level strategy enshrined in the one-pager further explained in the Gavi 5.0 Board paper (Doc 06), and with reference to Goal 3, Objective C, the Gavi Alliance Board agreed that:

a) Gavi’s post-transition support to former Gavi-eligible countries should be institutionalised and requested the Secretariat to develop and bring back to the Board an approach focusing on political advocacy, technical assistance, innovation, market shaping and catalytic financial support to jumpstart vaccine introductions.

b) Recognising that many never Gavi-eligible countries with GNI per capita of less than US$ 4,000 face similar challenges and contexts as former Gavi-eligible countries, the Secretariat should also explore options to engage with these countries based on the same set of modalities.
c) The Secretariat should also explore options to engage with never Gavi-eligible countries with GNI per capita of between US$ 4,000 and US$ 6,000 although based on the needs, the modalities of engagement may be different.

d) Engagement with former and never-eligible Gavi countries should account for no more than 3% of Gavi planned expenditure in the 2021-2025 period.

e) The decision on Gavi’s approach to engagement with never-eligible countries will require Board approval and will, therefore, follow the usual governance process including review by the Programme and Policy Committee prior to Board consideration.
Decision 14: Review of the Strategy For Papua New Guinea (1/2)

The Gavi Alliance Board:

a) **Approved**, as part of a tailored strategy to address the challenges in Papua New Guinea (“PNG”) and taking into account the request made by the Government of PNG to the Gavi Alliance Board in November 2018, that PNG be exceptionally granted an extension of the country’s “Accelerated Transition” period (Phase 2) from 2020 to 2025;

b) **Requested** Alliance partners to engage in PNG’s National Health Planning process to assist the Government to develop specific applications for Gavi Health System Strengthening and New Vaccine Support, and identify key national commitments to health system and immunisation strengthening on which Gavi support would be conditional;
c) **Requested** the Secretariat, in the context of the National Health Planning process and in consultation with the Government and Alliance partners, to develop an accountability framework and to organise annually a review with Alliance partners and the Government to assess progress against that accountability framework.

d) **Delegated** to the Secretariat the authority to apply policy flexibilities required to respond to the circumstances in PNG during the extended Accelerated Transition period, noting that the indicative cost of this Gavi support to PNG is estimated to be an amount of US$ 60 million; and

e) **Requested** the Secretariat to provide annual updates to the PPC and an update to the Board in 2023 on the progress of Gavi’s support to PNG.
Decision 15: Co-financing Arrangements for Inactivated Poliovirus Vaccine (IPV) Post 2020

The Gavi Alliance Board:

Approved support for inactivated poliovirus vaccine (IPV) based on a risk-based cost sharing approach of IPV between Gavi and countries which takes into account the epidemiologic risks of poliovirus re-emergence and country ability to share the cost of IPV. Under this approach the global withdrawal of bivalent oral poliovirus (bOPV) vaccine is used as a trigger for cost-sharing in order to ensure that existing financing for bOPV is not displaced (assumed to be US$ 0.60 per infant) from the polio programme. Thus the country financing no longer used for bOPV is used to contribute to the cost of IPV vaccine as follows: Initial Self-financing countries: Gavi fully finances IPV doses; Preparatory transition countries, Accelerated transition countries and Fully Self-Financing countries: Gavi fully finances IPV until bOPV cessation and at bOPV cessation, country funds US$ 0.60 per targeted infant with Gavi paying the remainder of IPV costs. This approach will be reviewed by the Board in 2022.
Thank you